GURUFOCUS.COM » STOCK LIST » USA » NYSE » Merck & Co Inc (NYSE:MRK) » Definitions » Cyclically Adjusted PS Ratio
Switch to:

Merck (NYSE:MRK) Cyclically Adjusted PS Ratio

: 5.18 (As of Today)
View and export this data going back to 1949. Start your Free Trial

As of today (2023-12-09), Merck's current share price is $103.75. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $20.03. Merck's Cyclically Adjusted PS Ratio for today is 5.18.

The historical rank and industry rank for Merck's Cyclically Adjusted PS Ratio or its related term are showing as below:

MRK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.92   Med: 4.22   Max: 6.07
Current: 5.19

During the past years, Merck's highest Cyclically Adjusted PS Ratio was 6.07. The lowest was 2.92. And the median was 4.22.

MRK's Cyclically Adjusted PS Ratio is ranked worse than
79.86% of 725 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs MRK: 5.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's adjusted revenue per share data for the three months ended in Sep. 2023 was $6.269. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $20.03 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merck's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 5.39 4.79 4.39 5.85

Merck Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.55 5.85 5.48 5.85 5.14

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PS Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.



Merck Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merck's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=103.75/20.03
=5.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Merck's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=6.269/129.8595*129.8595
=6.269

Current CPI (Sep. 2023) = 129.8595.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 3.820 98.326 5.045
201403 3.455 99.695 4.500
201406 3.708 100.560 4.788
201409 3.627 100.428 4.690
201412 3.632 99.070 4.761
201503 3.290 99.621 4.289
201506 3.433 100.684 4.428
201509 3.552 100.392 4.595
201512 3.630 99.792 4.724
201603 3.332 100.470 4.307
201606 3.530 101.688 4.508
201609 3.782 101.861 4.822
201612 3.645 101.863 4.647
201703 3.411 102.862 4.306
201706 3.608 103.349 4.533
201709 3.786 104.136 4.721
201712 3.822 104.011 4.772
201803 3.704 105.290 4.568
201806 3.882 106.317 4.742
201809 4.031 106.507 4.915
201812 4.175 105.998 5.115
201903 4.155 107.251 5.031
201906 4.544 108.070 5.460
201909 4.820 108.329 5.778
201912 1.621 108.420 1.942
202003 4.734 108.902 5.645
202006 3.688 108.767 4.403
202009 4.306 109.815 5.092
202012 4.309 109.897 5.092
202103 4.182 111.754 4.860
202106 4.489 114.631 5.085
202109 5.187 115.734 5.820
202112 5.334 117.630 5.889
202203 6.268 121.301 6.710
202206 5.745 125.017 5.968
202209 5.885 125.227 6.103
202212 5.428 125.222 5.629
202303 5.679 127.348 5.791
202306 5.922 128.729 5.974
202309 6.269 129.860 6.269

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (NYSE:MRK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merck Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (NYSE:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Cristal N Downing officer: Chief Comm. & Public Afrs Ofcr 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Michael A Klobuchar officer: EVP - Chief Strategy Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lisa Lecointe-cephas officer: SVP Chief Ethics & Com Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Dean Y Li officer: Executive VP & President, MRL 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Christine E Seidman director MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathy J Warden director 2980 FAIRVIEW PARK DRIVE, FALLS CHURCH VA 22042

Merck (NYSE:MRK) Headlines

From GuruFocus